Fecal microbiota transplantation (FMT)

The gut microbiome is an ecosystem living inside us: trillions of bacteria and other microbes that interact with digestion, immunity, metabolism and the molecules circulating through the body. That ecosystem changes with age, and scientists have repeatedly found differences between the microbiomes of younger, healthier people and those of older or frailer adults. The provocative question is whether those changes merely accompany aging—or whether changing the ecosystem itself can influence how people age.

Fecal microbiota transplantation, or FMT, is one of the most direct ways to test that idea. Instead of adding a single probiotic strain, FMT transfers an entire screened microbial community from a donor into a recipient. It is already used or investigated clinically for specific gastrointestinal conditions, but that does not mean it is an established longevity treatment. AgeBeacon separates those disease-specific uses from research that actually asks questions about aging, frailty or age-related disease.

Our registry search found 688 unique FMT trials, but almost all of them concern infections, inflammatory bowel disease and other conditions rather than aging. After relevance review, only one trial directly tests FMT as a healthy-aging intervention: a 210-person study examining oral FMT in aging and frailty, with outcomes including frailty, cognition, cardiovascular aging, physical function and biological markers. Thirteen additional trials are indirect evidence in Parkinson's or Alzheimer's disease.

That distinction is the heart of the evidence story. The microbiome is biologically fascinating, and FMT can clearly change microbial communities, but changing a microbiome is not the same as slowing human aging. AgeBeacon's literature pipeline also found 200 candidate papers across human, animal, mechanistic and clinical-significance searches; these are research leads, not 200 verified supportive studies. The direct healthy-aging trial is still recruiting and has no registry results yet, so there is currently no direct human aging outcome to score for efficacy. For now, FMT is an unusually interesting experiment in whether a complex living ecosystem can modify aging-related physiology—not evidence that microbiome transplantation extends healthy lifespan.